VhH anti‐thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow

Thrombomodulin on endothelial cells can form a complex with thrombin. This complex has both anticoagulant properties, by activating protein C, and clot‐protective properties, by activating thrombin‐activatable fibrinolysis inhibitor (TAFI). Activated TAFI (TAFIa) inhibits plasmin‐mediated fibrinolysis.

[1]  P. Declerck,et al.  Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review , 2021, International journal of molecular sciences.

[2]  C. Maas,et al.  A head-to-head comparison of conjugation methods for VHHs: Random maleimide-thiol coupling versus controlled click chemistry , 2019, International journal of pharmaceutics: X.

[3]  E. Conway,et al.  Exploring traditional and nontraditional roles for thrombomodulin. , 2018, Blood.

[4]  C. Maas,et al.  Live-cell Imaging of Platelet Degranulation and Secretion Under Flow. , 2017, Journal of visualized experiments : JoVE.

[5]  A. Gils,et al.  Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice , 2016, Stroke.

[6]  P. Liaw,et al.  Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells , 2016, Journal of thrombosis and haemostasis : JTH.

[7]  S. Muyldermans,et al.  In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody , 2014, Thrombosis and Haemostasis.

[8]  C. Maas,et al.  Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy , 2014, Circulation.

[9]  C. Maas,et al.  A nanobody-based method for tracking factor XII activation in plasma , 2013, Thrombosis and Haemostasis.

[10]  S. Muyldermans,et al.  Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor , 2010, Journal of thrombosis and haemostasis : JTH.

[11]  S. Diamond,et al.  Microfluidic focal thrombosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear‐resistance of platelet aggregates , 2008, Journal of thrombosis and haemostasis : JTH.

[12]  E. Bird,et al.  Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis , 2007, Journal of Thrombosis and Thrombolysis.

[13]  H C Hemker,et al.  The limits of simulation of the clotting system , 2006, Journal of thrombosis and haemostasis : JTH.

[14]  A. Gils,et al.  Modulation of TAFI function through different pathways – implications for the development of TAFI inhibitors , 2005, Journal of thrombosis and haemostasis : JTH.

[15]  F. Rosendaal,et al.  Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. , 2004, Blood.

[16]  J. Weitz,et al.  Evidence That Both Exosites on Thrombin Participate in Its High Affinity Interaction with Fibrin* , 2003, Journal of Biological Chemistry.

[17]  H. Coenraad Hemker,et al.  Calibrated Automated Thrombin Generation Measurement in Clotting Plasma , 2003, Pathophysiology of Haemostasis and Thrombosis.

[18]  C. Kluft,et al.  Stabilization Versus Inhibition of TAFIa by Competitive Inhibitors in Vitro * , 2003, The Journal of Biological Chemistry.

[19]  M. Nesheim,et al.  Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis , 2003, Journal of thrombosis and haemostasis : JTH.

[20]  C. Esmon,et al.  The protein C pathway , 2000, Chest.

[21]  A. Hamsten,et al.  Plasma Procarboxypeptidase U in Men with Symptomatic Coronary Artery Disease , 2000, Thrombosis and Haemostasis.

[22]  Weiqi Wang,et al.  Elements of the Primary Structure of Thrombomodulin Required for Efficient Thrombin-activable Fibrinolysis Inhibitor Activation* , 2000, The Journal of Biological Chemistry.

[23]  F. Rosendaal,et al.  Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. , 2000, Blood.

[24]  J. Shafer,et al.  Characterization of Plasmin-mediated Activation of Plasma Procarboxypeptidase B , 1999, The Journal of Biological Chemistry.

[25]  M. Nagashima,et al.  Identification and Characterization of Two Thrombin-activatable Fibrinolysis Inhibitor Isoforms , 1998, Thrombosis and Haemostasis.

[26]  K. Kokame,et al.  Activation of Thrombin-activable Fibrinolysis Inhibitor Requires Epidermal Growth Factor-like Domain 3 of Thrombomodulin and Is Inhibited Competitively by Protein C* , 1998, The Journal of Biological Chemistry.

[27]  P. A. von dem Borne,et al.  Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. , 1997, The Journal of clinical investigation.

[28]  P. Simioni,et al.  An Antifibrinolytic Mechanism Describing the Prothrombotic Effect Associated with Factor VLeiden* , 1996, The Journal of Biological Chemistry.

[29]  P. A. von dem Borne,et al.  Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. , 1995, Blood.

[30]  J. Parkinson,et al.  Alanine-scanning mutagenesis of the epidermal growth factor-like domains of human thrombomodulin identifies critical residues for its cofactor activity. , 1993, The Journal of biological chemistry.

[31]  G. Broze,et al.  Factor XI activation in a revised model of blood coagulation , 1991, Science.

[32]  E. Davie,et al.  Factor XI deficiency in Ashkenazi Jews in Israel. , 1991, The New England journal of medicine.

[33]  K Fujikawa,et al.  Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. , 1991, The Journal of biological chemistry.

[34]  S. Yamamoto,et al.  A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. , 1989, The Journal of biological chemistry.

[35]  E. Conway.  Thrombomodulin and its role in inflammation , 2011, Seminars in Immunopathology.

[36]  B. Bouma,et al.  Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis? , 2006, Annals of medicine.

[37]  M. Halks-Miller,et al.  Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. , 2002, The Journal of clinical investigation.

[38]  J. Meijers,et al.  Regulation of Fibrinolysis in Plasma by TAFI and Protein C Is Dependent on the Concentration of Thrombomodulin , 2001, Thrombosis and Haemostasis.

[39]  C. Cambillau,et al.  Camelid heavy-chain variable domains provide efficient combining sites to haptens. , 2000, Biochemistry.